To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

  • STATUS
    Recruiting
  • participants needed
    249
  • sponsor
    Boryung Biopharma Co., Ltd.
Updated on 4 August 2021
Investigator
Sunhye IM
Primary Contact
Jeonbuk National University Hospital (0.0 mi away) Contact
+23 other location

Summary

The study objective is to assess the immunogenicity and safety of DTaP-IPV combination vaccine administered as a boosting dose to healthy 4 to 6-year-old children who received three doses of primary immunization against diphtheria, tetanus, pertussis, and polio.

Details
Condition Pertussis Vaccine, Pertussis, Diphtheria, Tetanus, Poliomyelitis, whooping cough, polio
Treatment DTaP-IPV combination vaccine
Clinical Study IdentifierNCT04618640
SponsorBoryung Biopharma Co., Ltd.
Last Modified on4 August 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note